P001

This document summarizes a clinical trial that compared two adjuvant chemotherapy regimens for node-positive breast cancer patients: 1) six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) or 2) three cycles of FEC followed by three cycles of docetaxel (FEC-D). The trial found that the sequential FEC-D regimen significantly improved disease-free survival and overall survival compared to FEC alone, with a favorable safety profile. The FEC-D regimen was associated with more febrile neutropenia, stomatitis, edema and nail disorders but fewer cardiac events due to the lower cumulative anthracycline dose.